Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration

NCT06116890 is registered in ClinicalTrials.gov with Kyowa Kirin Co., Ltd. as lead sponsor.

NCT NCT06116890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06116890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration
Lead sponsor
Kyowa Kirin Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2024
Completion date
July 1, 2026
Enrollment
170 (actual)
Sites
84

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration (namd)